SNURF is a small RING finger protein that binds the zinc finger region of steroid hormone receptors and enhances Sp1-and androgen receptor-mediated transcription in COS and CV-1 cells. In this study, we show that SNURF coactivates both wild-type estrogen receptor ␣ (ER␣) (4-fold)-and HE19 (ER␣ deletion of activation function 1 (AF1)) (210-fold)-mediated activation of an estrogen-responsive element promoter in ZR-75 cells. In mammalian two-hybrid assays in ZR-75 cells SNURF interactions were estrogen (E2)-dependent and were not observed with the antiestrogen ICI 182,780. ER␣ interacted with multiple regions of SNURF; SNURF interactions with ER␣ were dependent on AF2, and D538N, E542Q, and D545N mutations in helix 12 abrogated both SNURF-ER␣ binding and coactivation. Moreover, peptide fusion proteins that inhibit interactions between helix 12 of ER␣ with LXXLL box-containing proteins also blocked ER␣ coactivation by SNURF. However, cotransfection of SNURF with prototypical steroid receptor coactivators 1, 2, and 3 that contain LXXLL box motifs did not enhance E2 responsiveness, whereas TATA-binding protein (TBP) and SNURF cooperatively coactivated ER␣-mediated transactivation. The results are consistent with a unique model for cooperative coactivation of ER␣ that requires ligand binding, repositioning of helix 12, recruitment of TBP, and interaction with SNURF, which binds both ER␣ and TBP.
The nuclear receptor (NR) 1 superfamily of transcription factors includes the steroid/thyroid hormone, retinoid, and vitamin D receptors and a growing number of orphan receptors for which endogenous ligands have not yet been identified (1) (2) (3) (4) (5) (6) . The orphan pregnane (steroid) X receptor, constitutive androstane receptor, and peroxisome proliferator-activated receptor ␣ bind structurally diverse steroidal compounds, drugs, and xenobiotics and induce members of the CYP2, CYP3, and CYP4 family of P450 isoenzymes (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . NRs share common structural features or domains, and these have been extensively characterized for most ligand-activated NRs (1) (2) (3) (4) (5) (6) . For example, the two forms of the estrogen receptor (ER␣ and ER␤) contain a highly conserved DNA binding domain C (DBD) (97% homology for human ERs) in the central portion of both proteins (20 -23) . Similarities between the DBDs of NRs are due to their zinc finger motifs, which directly bind DNA; however, despite these similarities, subtle structural differences are important for sequence-specific interactions of these transcription factors (2) . The N-terminal and C-terminal domains (A/B and E/F for the ER) of NRs contain activation function 1 (AF1) and AF2, respectively, and the ligand binding domain is also located in AF2. The expression and functions of AF1/AF2 are highly variable among NRs; however, for some NRs, such as the androgen receptor (AR), both domains interact to enhance transcriptional activation.
Several different classes of proteins interact with NRs to enhance or inhibit their activity as trans-acting factors, and these interacting proteins include coactivators, cointegrators, corepressors, and multiple proteins associated with the basal transcription machinery (reviewed in Refs. 24 -31) . Ligand-dependent interactions of NR AF2 domains with p160 steroid receptor coactivators (SRCs), through their LXXLL motifs or NR boxes, have been extensively investigated (32) (33) (34) (35) . SRCs and other coactivators were initially isolated using two-hybrid assays with AF2 domains as bait, and there is also evidence that for some hormone receptors, coactivators also interact with AF1 to enhance transactivation (36, 37) . SRCs and cointegrators such as p300/CBP and p300/CBP-associated factor (PCAF), which enhance transcriptional activation of NRs, also exhibit histone acetyltransferase activity, which may also contribute to interactions of NRs with their cognate response elements and the basal transcriptional machinery (38 -41) . In addition, members of a complex group of related proteins that include vitamin D receptor-interacting proteins (DRIP), cofactors required for Sp1 (CRSP), activated recruited cofactors, and thyroid hormone-associated proteins (TRAP) also coactivate ER and other NRs (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) . In contrast, these proteins do not exhibit histone acetyltransferase activity, and a recent study using a chromatin immunoprecipitation assay showed that both SRC-3 and DRIP205 are recruited to the estrogen-responsive region of the cathepsin D gene promoter after treatment of MCF-7 cells with 17␤-estradiol (E2) (53) .
SNURF is a small RING finger protein that was originally isolated in a yeast two-hybrid assay using the zinc finger region containing the DBD and one-third of the hinge region of the AR as bait (54, 55) . SNURF also interacts with the corresponding region of the ER and progesterone receptor (PR), and a RING finger mutant of SNURF (CS1) coactivates ligand-activated AR-dependent transactivation in COS-1 and CV-1 cotransfected with promoters containing androgen/glucocorticoid response elements. SNURF also enhances basal transcription from various hormone-responsive promoters and from promoters containing GC-rich sites that bind the Sp1 transcription factor (55) . This study investigates physical and functional interactions of SNURF with human ER␣ (hER␣) in ZR-75 breast cancer cells, and the results show that SNURF coactivates hER␣-dependent transcription in ZR-75 cells transfected with a construct (pERE 3 ) containing three tandem estrogenresponsive elements (EREs) linked to a luciferase reporter gene. Although SNURF does not directly interact with the AF2 domain of hER␣, SNURF coactivation of ER␣ is cooperative and requires ligand-dependent repositioning of helix 12 and recruitment of TATA-binding protein (TBP).
MATERIALS AND METHODS
Chemicals, Biochemicals, and Gifts-Fetal bovine serum was obtained from Summit Biotechnology (Fort Collins, CO). [␥-
32 P]ATP (3000 Ci/mmol) was purchased from PerkinElmer Life Sciences. Poly[d(I-C)] and restriction enzymes (HindIII, SalI, BamHI) were purchased from Roche Molecular Biochemicals. RPMI 1640 media, phenol-free Dulbecco's modified Eagle's medium/F-12 media, phosphate-buffered saline, E2, and 100ϫ antibiotic/antimycotic solution were purchased from Sigma; 5ϫ luciferase lysis buffer and luciferin were purchased from Promega (Madison, WI). Reagents for ␤-galactosidase analysis were purchased from Tropix (Bedford, MA). Human ER␣ expression plasmid was originally supplied by Dr. Ming-Jer Tsai (Baylor College of Medicine, Houston, TX) and recloned into pcDNA3 (Invitrogen). The pERE 3 reporter containing three consensus ERE sites linked to a luciferase gene was created by cloning an oligonucleotide with three ERE elements into BamHI-HindIII cut pXP-2 plasmid (American Type Culture collection (ATCC), Manassas, VA). Plasmid preparation kits were purchased from Qiagen (Santa Clarita, CA); 40% polyacrylamide was obtained from National Diagnostics (Atlanta, GA). ICI 182,780 was provided by Dr. Alan Wakeling (Zeneca Pharmaceuticals, Macclesfield, UK). Expression plasmids for ER␣ mutants with deletions of amino acid 1-178 (HE19) or 185-252 (HE11) were kindly provided by Dr. Pierre Chambon, and TBP expression plasmid was obtained from Dr. Laszlo Tora (Institute de Genetique et Biologie Moleculaire et Cellulaire, Illkirch, France). ER␣-null and ER␣-AF1 were derived from HE19, and ER␣ containing D538N, E542Q, and D545N mutations and were kindly provided by Dr. Donald McDonnell (Duke University, Durham, NC). cDNAs for these constructs were then subcloned into the EcoRI site of pcDNA3.1. The CMV promoter-driven expression constructs (pcDNA3.1) for wild type, ⌬1-20, ⌬31-65, ⌬66 -98, ⌬99 -118, ⌬121-147, ⌬157-194, ⌬178 -194, CS1, CS2, and CS3 SNURF coactivator protein were previously described (54, 55) . Expression plasmids for SRC-1, GRIP-1 (SRC-2), and SRC-3 (AIB1) were provided by Dr. Bert O'Malley (Baylor College of Medicine, Houston, TX), Dr. Michael Stallcup (University of Southern California, Los Angeles, CA), and Dr. Paul Meltzer (NCI, National Institutes of Health, Bethesda, MD), respectively. The expression plasmid for the GRIP-1 NR-box polypeptide GAL4 fusion protein was provided by Dr. Donald McDonnell (Duke University, Durham, NC). All other chemicals and biochemicals were the highest duality available from commercial sources.
Transient Transfection Assays-ZR-75 breast cancer cells were obtained from ATCC and grown and maintained in RPMI 1640 supplemented with 10% fetal bovine serum. Cells were seeded onto 12-well plates at a concentration of 2.75 ϫ 10 5 cells/well in phenol-free Dulbecco's modified Eagle's medium/F-12 media supplemented with 2.5% charcoal-stripped fetal bovine serum. After 18 h, cells were transfected by the calcium phosphate method with 1 g of pERE 3 reporter plasmid, 0.25 g of a CMV ␤-gal expression plasmid, the appropriate hER␣ expression plasmid, and the appropriate SNURF expression construct. After 6 -8 h, cells were shocked with 25% glycerol for 20 s, rinsed once with 1ϫ phosphate-buffered saline, and dosed with either Me 2 SO or 10 nM E2 in Dulbecco's modified Eagle's medium/F-12 plus 2.5% charcoalstripped fetal bovine serum for 36 h. Cells were harvested by scraping the plates in 100 l of 1ϫ lysis buffer. Twenty l of the cell lysate was used for performing luciferase assays on a Lumicount Luminometer (Packard Instrument Co.). Twenty l of the cell lysate was used for running a ␤-gal analysis on a luminometer. Normalized luciferase values were calculated by dividing the luciferase value by the ␤-gal value for a given sample. Results are expressed as means Ϯ S.E. and compared with the Me 2 SO control group (arbitrarily set at 1) for each set of experiments.
Western Blot Analysis-For Western analysis, ZR-75 cells were seeded and transfected as described above and harvested in 100 l of 1ϫ lysis buffer. After luciferase and ␤-gal assays were performed, 10 l of 3 M NaCl was added to the remaining 60 l of extract to obtain maximal protein yield. The lysates were incubated on ice for 1 h with intermittent vortexing followed by centrifugation (15,000 ϫ g, 5 min, 4°C). Equal amounts of protein from each treatment group were separated by SDS-PAGE and transferred to polyvinylidene difluoride membrane using a Bio-Rad Trans-Blot electrophoretic transfer cell (transfer buffer: 48 mM Tris, 39 mM glycine, 0.025% SDS). Membranes were blocked for 30 min in Blotto (5% milk ϩ TBS (10 mM Tris-HCl, pH 8.0,150 mM NaCl), 0.05% Tween 20), probed with polyclonal antibodies for ER␣ (sc-544 purchased from Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at a dilution of 1:1000 in Blotto for 5 h, washed 2 ϫ 5 min in TBS ϩ 0.05% Tween 20, and probed with secondary peroxidase-conjugated antibody (1:5000 in Blotto) for 2 h. The membranes were then washed 3 ϫ 5 min in TBS ϩ 0.05% Tween 20, 1 ϫ 5 min in TBS, and visualized using the ECL detection system (PerkinElmer Life Sciences). Quantitation of the Western blot was performed using a Sharp JX-330 scanner (Sharp Corp., Mahwah, NJ) and Zero-D Scanalytics software (Scanalytics Corp., Billerica, MA).
Cloning and Oligonucleotides-Plasmid pERE 3 was created by cloning three consensus ERE elements (GGTCANNNTGACC, N is a nucleoside) separated by 10 base pairs into pXP-2, 30 base pairs upstream of the TATA box. ER␣-GAL4 fusion proteins were constructed as follows. First, the GAL4DBD fusion expression vector pM (CLONTECH, Palo Alto, CA) was digested with BamHI and HindIII, and the oligo sequence GATCCGTGTCTGCAGACGTCGACA was inserted into this digested vector. This oligo was added to create more space between restriction enzymes BamHI and SalI in the polylinker of vector pM, providing a more efficient digestion of these two enzymes when cut simultaneously. This new vector, pM(ϩ10), was then used for construction of each of the pM-ER plasmids. The cDNA for each ER deletion or mutant was PCRamplified with the primers and plasmids indicated in Table I .
After PCR amplification, each ER cDNA fragment was digested with BamHI and SalI and cloned into pM(ϩ10) digested with BamHI/SalI to give pM-ER, pM-AF1 ER␣, pM-HE11, pM-He19, pM-ER␣-null, and Upper, GTG GAT CCG TGC CAA GGA GAC TCG CTA CTG T pcDNA3ER␣ Lower, same wt ER pM-AF2. All pM-ER␣ constructs were sequenced to confirm that no unintended mutations were incorporated from Taq polymerase.
SNURF-VP16 constructs were made as indicated; initially pVP16 (CLONTECH) was digested with BamHI and HindIII followed by PCR amplification of SNURF cDNA from each of the mutant or deletion SNURF expression plasmids. The primers used for this contained BamHI (upper) or HindIII (lower) linker DNA and are indicated in Table II .
After amplification, the cDNA was digested with BamHI/HindIII and subcloned into the pVP16 vector digested with these same enzymes to give VP-wt SNURF, VP-⌬1-20 SNURF, VP-⌬31-65 SNURF, VP-⌬66 -98 SNURF, VP-⌬99 -118 SNURF, VP-⌬121-147 SNURF, VP-⌬157-194 SNURF, VP-⌬178 -194 SNURF, VP-CS1 SNURF, VP-CS2 SNURF, and VP-CS3 SNURF.
Mammalian Two-hybrid Assay-Protein-protein interactions between ER and SNURF were examined in ZR-75 cells using the mammalian MATCHMAKER two-hybrid kit (CLONTECH). For determination of regions on SNURF that are important for physically interacting with ER␣, ZR-75 cells were transfected by the calcium phosphate method with 1 g of 5ϫGAL-luciferase, 500 ng of pM-ER␣, and either 250 ng pVP-16-wt-SNURF or 250 ng each of the pVP-SNURF mutants or deletions. Six to 8 h after transfection, cells were shocked with 25% glycerol for 20 s, washed 1ϫ with phosphate-buffered saline, and then dosed with either 10 nM E2 or vehicle alone (Me 2 SO). For determination of the regions on ER␣ that are necessary for interacting with SNURF, ZR-75 cells were transfected with 1 g of 5ϫGAL-luciferase, 500 ng of pM-wt ER, or 500 ng of pM-mutated or deleted ER and 250 ng of pVP-16-wtSNURF.
Chromatin Immunoprecipitation Assay-Breast cancer cells were grown in 60-mm tissue culture plates to 80 -95% confluency, transfected pERE 3 , glycerol-shocked, and grown in serum-free medium for 3 days. Cells were then treated with E2 for various times, and formaldehyde was then added to the medium to give a 1% solution. After mixing on a rotary shaker for 10 min at 20°C, glycine was then added (final concentration of 0.125 M); after further incubation for 10 min, the medium was removed, and cells were washed with phosphate-buffered saline (containing 1 mM phenylmethylsulfonyl fluoride), scraped, and collected by centrifugation. Cells were then resuspended in swell buffer (85 mM KCl, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, and aprotinin at pH 8.0) and homogenized, and nuclei were isolated by centrifugation at 1500 ϫ g for 30 s. Nuclei were then resuspended in sonication buffer (1% SDS, 10 mM EDTA, 50 mM Tris at pH 8.1) and sonicated for 45-60 s to obtain chromatin with appropriate fragment lengths of 500-1000 base pairs. The sonicated extract was then centrifuged at 15,000 ϫ g for 10 min at 0°C, separated into aliquots, and stored at Ϫ70°C until used. The cross-linked chromatin preparations were diluted in buffer (1% Triton X, 100 mM NaCl, 0.5% SDS, 10 mM Tris/1 mM EDTA at pH 8.1), and 20 l of Ultralink protein A or G or A/G beads (Pierce) was added per 100 l of chromatin and incubated for 4 h at 4°C. A 200-l aliquot was saved and used as the 100% input control. This aliquot was treated at 65°C to reverse crosslinks, and DNA was purified as described below. The cross-linked mixtures were then centrifuged to remove the beads; salmon sperm DNA, specific ER␣ antibodies, and 20 l of Ultralink beads were added, and the mixture was incubated for 6 h at 4°C. Samples were then centrifuged; beads were resuspended in dialysis buffer, vortexed for 5 min at 20°C, and centrifuged at 15,000 ϫ g for 10 s; beads were then resuspended in immunoprecipitation buffer (11 mM Tris, 500 mM LiCl, 1% Nonidet P-40, 1% deoxycholic acid at pH 8.0) and vortexed for 5 min at 20°C. The procedures with the dialysis and immunoprecipitation buffers were repeated (3-4ϫ), and beads were then resuspended in elution buffer (50 nM sodium bicarbonate, 1% SDS, 1.5 g/m sonicated salmon sperm DNA), vortexed, and incubated at 65°C for 15 min.
Supernatants were then isolated by centrifugation and incubated at 65°C for 6 h to reverse protein-DNA cross-links. Wizard PCR kits were used for additional DNA cleanup, and PCR was used to detect the presence of promoter regions immunoprecipitated with the different ER␣ antibodies. SNURF antibodies were previously described (54, 55) . The following primers were used for PCR analysis of the transfected pERE 3 construct and the E2-responsive Ϫ294 to Ϫ511 region of the cathepsin D gene promoter: cathepsin D forward (Ϫ294), 5Ј-TCC AGA CAT CCT CTC TGG AA-3Ј, and reverse (Ϫ54), 5Ј-GGA GCG GAG GGT CCA TTC-3Ј; cathepsin D forward control (ϩ2469), 5Ј-TGC ACA AGT TCA CGT CCA TC-3Ј, and reverse (ϩ2615), 5Ј-TGT AGT TCT TGA GCA CCT CG-3Ј; pERE3 forward (6128), 5Ј-GTT TGT CCA AAC TCA TCA ATG-3Ј, and reverse (105), 5Ј-CTT TAT GTT TTT GGC GTC TTC-3Ј. As a negative control, immunoprecipitation of the ϩ2469 to ϩ2615 region of the cathepsin D gene promoter was also determined and confirmed by both PCR and PCR combined with Southern analysis using a specific probe for this region of cathepsin D.
Statistical Analysis-Statistical significance was determined by analysis of variance and Scheffe's test, and the levels of probability are noted. Results are expressed as means Ϯ S.E. for at least three separate (replicate experiments for each treatment group.
RESULTS

Coactivation of ER␣-mediated Transactivation in ZR-75
Cells-ZR-75 breast cancer cells are E2-responsive and primarily express ER␣. E2 did not significantly induce reporter gene activity in this cell line after transfection with pERE 3 ; however, after cotransfection with 7.5 ng of ER␣ expression plasmid, a 5-fold induction of luciferase activity was observed (Fig. 1A) . Similar results have previously been observed in ER-positive MCF-7 breast cancer cells where cotransfection of ER␣ is required for induction of reporter gene activity by E2 using constructs containing EREs, AP-1 promoters, or E2-responsive regions from the pS2, cathepsin D, c-fos, and PR gene promoters (56 -68) . Cotransfection of ER␣ is also required for E2-induced transactivation using constructs containing several E2-responsive GC-rich gene promoter inserts that interact with ER␣/Sp1, and this is due to overexpression of the transfected reporter plasmids (69 -79) . Thus, ER-positive breast cancer cells can be used for analysis of gene promoters to determine functional interactions of proteins associated with E2 responsiveness in a breast cancer cell context.
The results in Fig. 1A show that E2 induces reporter gene activity in ZR-75 cells transfected with pERE 3 and ER␣, and the induction response is enhanced by 4-fold after cotransfection with 10 -150 ng of SNURF expression plasmid. To determine the cell specificity of coactivation by SNURF, we also tested other breast (MCF-7) and non-breast (HeLa) cancer cells, and similar results were observed in ZR-75, MCF-7, and HeLa cells. SNURF only enhances ligand-induced responses, and basal activity in cells treated with solvent (Me 2 SO) varied Ͻ1.5-fold over the 10 -150-ng range of SNURF expression plasmid. Coactivation of E2 responsiveness by SNURF was not due to up-regulation of ER␣ in these cells since immunoreactive protein levels were not significantly altered or slightly decreased in cells cotransfected with 10 or 20 ng of SNURF expression plasmid, whereas maximal coactivation was ob- (Fig. 1B) . Expression of SNURF in ZR-75 and other cancer cell lines was also investigated by Northern blot analysis. SNURF mRNA was expressed in multiple breast, endometrial, liver, and osteosarcoma cell lines but not in Drosophila Schneider SL-2 cells (data not shown), indicating that SNURF is widely expressed in mammalian cells.
The importance of AF1 and AF2 domains of ER␣ for SNURF coactivation was investigated in ZR-75 cells cotransfected with pERE 3 and HE19, ER␣-AF1, or ER␣-null expression plasmids and different amounts of SNURF expression plasmid (Fig. 2) . In cells transfected with HE19 and pERE 3 , E2 induced a 7-fold increase in reporter gene activity, which is consistent with AF2-dependent activity of ER␣, and cotransfection with 5-50 ng SNURF expression plasmid coactivated this response by Ն10-fold ( Fig. 2A) (maximal enhancement was observed using 25 ng of SNURF). SNURF alone did not enhance basal activity Ͼ1.5-fold, and coactivation by SNURF was observed only for the ligand-activated response. The increased coactivation of HE19 by SNURF compared with that observed for wild-type ER␣ suggests an inhibitory role for the AF1 domain of ER␣. E2 also induced luciferase activity in ZR-75 cells transfected with pERE 3 and ER␣-AF1, which contained mutations in AF2 (D538N, E542Q, and D545N) that block AF2-dependent interactions with coactivators and possibly other transcriptionally important AF2-interacting proteins (Fig. 2B) . However, cotransfection with 5-500 ng of SNURF did not significantly coactivate AF1-dependent induction of luciferase activity by E2, suggesting that coactivation by SNURF required intact AF2 function. The results illustrated in Fig. 2C show that luciferase activity was induced by E2 in cells transfected with ER␣-null, and previous studies report that this construct is significantly hormone-responsive in some cell types (36) . However, in cells cotransfected with ER␣-null and SNURF, coactivation was not observed, indicating that the D538N, E542Q, and D545N mutations in helix 12 of the AF2 domain were critical for SNURF activity.
Inhibition of SNURF Coactivation by GRIP-1 Box PeptideThe GRIP-1 box peptide contains the GRIP-1 coactivator LXXLL NR box (TKLLQLL) fused to the DNA binding domain of the yeast GAL4 protein and cloned into the pMsx vector as described (80) . Previous studies show that the GRIP-1 NR-box peptide binds to helix 12 of ER␣ (80) , and the results in Fig. 3A show that the NR-box peptide expression plasmid (10 -50 ng) decreases ER␣-or SNURF/ER␣-mediated transactivation from pERE 3 . E2 induces luciferase activity in ZR-75 cells transfected with pERE 3 and HE19 (20-fold), and cotransfection with the GRIP-1-box peptide expression plasmid (10 -640 ng) inhibited the induction response. Moreover, in cells cotransfected with pERE 3 , HE19, and SNURF expression plasmid (25 ng), hormone-induced transactivation was significantly decreased after cotransfection with 10 -640 ng of GRIP-1 NR-box expression plasmid. The results in Figs. 3, A and B, show that the GRIP-1 box peptide readily reverses coactivation by SNURF, suggesting that SNURF coactivation must be linked to liganddependent repositioning of helix 12 and recruitment of other AF2-interacting proteins. These data also rule out the possibility of potential conformational problems associated with the point mutations in ER␣-AF1 and ER␣-null.
Coactivation of ER␣ by Wild-type and Deletion Mutants of SNURF-Previous studies demonstrate that wild-type SNURF coactivates AR-dependent transactivation and activation of Sp1-dependent GC-rich promoter-reporter constructs (54, 55).
Functional SNURF-Sp1 interactions are dependent on the Cterminal RING finger domain, whereas SNURF coactivation of AR-mediated transactivation was dependent on several regions of SNURF, including the N-terminal 20 amino acids, amino acids 31-65, and amino acids 66 -98. Domains of SNURF required for coactivation of ER␣ were determined in ZR-75 cells cotransfected with ER␣ (7.5 ng) expression plasmid, pERE 3 , and wild-type or mutant SNURF expression plasmids (15 ng) (Fig. 4A) . The results indicated that both C-terminal and Nterminal regions of SNURF were required for coactivation of ER␣, and for the series of deletion constructs, only amino acids 66 -98 could be deleted without affecting the activity of SNURF as a coactivator. In contrast, this same region was required for enhancement of AR-dependent transactivation (55) . Interestingly, the pattern of coactivation of ER␣ and AR was similar for the zinc finger mutants in the C-terminal RING domain; CS1 (C136S and C139S) coactivated both ER␣ and AR, whereas CS2 (C177S and C180S) and CS3 (C136S, C139S, C177S, and C180S) did not coactivate either hormone receptor. In contrast, wild-type SNURF did not coactivate an androgen response element-dependent promoter in CV-1 or COS cells (55), whereas wild-type SNURF caused a 2-4-fold ligand-dependent enhancement of ER␣-mediated transactivation (Figs. 1-4) .
Interaction of ER␣ with Wild-type and Mutant SNURFInteractions between ER␣ and different domains of SNURF were determined in a mammalian two-hybrid assay in ZR-75 cells using pM-ER␣, which expresses the DBD-GAL4-ER␣ fusion protein, pGAL4 5 (five tandem GAL4 response elements linked to a luciferase reporter gene), and VP16 activation domain fusions (VP) of wild-type and mutant SNURF. Interactions of pM-ER␣ and VP-SNURF deletion mutants were estrogen-dependent, and in the absence of ligand, only low levels of reporter gene activity were observed. In cells transfected with pM-ER␣ and VP16 alone (empty vector), E2 induced an ϳ4-fold increase in reporter gene activity (Fig. 4B ).
This background activity is due to intrinsic transcriptional activity of ER; however, this response was enhanced (2-fold) in cells transfected with VP-SNURF. Increased transcriptional activity is the result of a protein-protein interaction between ER␣ and SNURF that brings the activation domain of VP-16 in close proximity of the GAL promoter. Enhanced transactivation was observed in this assay for all but two of the VP16-variant/mutant SNURF constructs, namely VP-⌬31-65SNURF and VP-CS3SNURF. Thus, deletion of amino acids 31-65 and mutation of both zinc fingers in the RING domain of SNURF resulted in loss of ER␣-SNURF interaction, and this correlates with the failure of ⌬31-65SNURF and CS3SNURF to coactivate ER␣ action in functional assays using pERE 3 (Fig.  4A) . In contrast, other deletions/mutants that resulted in loss of functional coactivation of ER␣ (Fig. 4A) did not affect binding of SNURF and ER␣, suggesting a role for other proteins in coactivation of ER␣ by SNURF.
Interactions of SNURF with ER␣ were also investigated in a mammalian two-hybrid assay in ZR-75 cells using VP-SNURF and GAL4-DBD fusion proteins with different regions of ER␣. All interactions were estrogen-dependent, and VP-SNURF did not interact with pM-ER␣ in the presence of the antiestrogen ICI 182,780 (Fig. 4C) . Because each pM-ER fusion protein has some background activity on pGAL4 5 , binding of GAL4 fusion proteins with VP-SNURF were expressed as fold-induction compared with activity observed with the VP16 empty vectors (Fig. 4D) (a fold induction of 1 indicates that the proteins do not interact). Protein-protein interactions were observed for pM-ER␣ and pM-11C with VP-SNURF, indicating that the DBD of ER␣ was not required for this interaction, although yeast twohybrid assays show direct binding of SNURF with the zinc finger regions of the ER, AR and the PR (54) . VP-SNURF did not interact with the AF2 domain of ER␣ (Fig. 4D ). This rules out one possible explanation suggested by the GRIP-1 NR-box data (Fig. 3) , namely that coactivation by SNURF requires direct interaction with the ER␣-AF2 domain. VP-SNURF also weakly interacted with HE19 (DBD ϩ AF2) but not with ER␣-AF1 or ER␣-null (DBD ϩ AF2 that contains D538N, E542Q, and D545N mutations) that block interactions with LXXLL motifs and other AF2-interacting proteins. HE19 and ER␣ differ from ER␣-null and ER␣-AF1 only with respect to the three mutations in helix 12 of the AF2 domain. It is clear that although AF2 does not directly bind SNURF, sequences within this domain enhance SNURF binding to the DBD hinge regions of ER␣ (i.e. compare HE19 versus ER␣-null). Interactions of VP-SNURF with HE11 suggests that SNURF also binds the AF1 domain of ER␣; however, HE11 is not active in functional assays with cells transfected with pERE 3 .
Interactions of ER␣ and SNURF were also investigated in ZR-75 cells by chromatin immunoprecipitation assays (Fig. 5) . Two different ER␣ antibodies (Santa Cruz Biotechnology) were used to immunoprecipitate cross-linked chromatin from the E2-responsive regions of the transfected pEREs and the Ϫ294 to Ϫ54 region of the endogenous cathepsin D gene promoter (63, 64, 67, 70) . SNURF and ER␣ (D12) antibodies immunoprecipitated the ERE promoter region of transfected pERE 3 in untreated cells (zero time) and after treatment with E2 for 15 min (Fig. 5, panel A) , indicating that both SNURF and ER␣ are associated with the ERE promoter. The two ER␣ antibodies differentially recognized ER␣ bound to the ERE, suggesting that treatment with E2 induced conformational changes in ER␣ and associated nuclear factors that masked the antibody epitope. Similar results were obtained with ER␣ antibodies for immunoprecipitation of the E2-responsive region of the cathepsin D gene in untreated cells (Fig. 5, panel B) ; however, both antibodies immunoprecipitated the cathepsin D gene promoter in cells treated with E2 for 15 or 30 min. The ϩ2469 to ϩ2615 region of the promoter (exon 2) does not contain ER␣ binding sites, and chromatin containing this sequence is not immunoprecipitated by ER␣ antibodies (panel C). We also used ER␣ and SNURF antibodies to investigate protein interactions with exon 2, which were analyzed by PCR and confirmed by Southern analysis (Fig. 6D) . The results show that ER␣ and SNURF did not interact with exon 2; moreover, using this approach we could also detect SNURF interactions with the cathepsin D gene promoter (Ϫ294 to Ϫ54) (data not shown). ER␣ antibodies did not immunoprecipitate the E2-responsive ERE (transfected) or cathepsin D promoter in cells incubated for longer FIG. 3 . GRIP1 NR-box peptide competition experiments. A, effects of GRIP1 NR-box peptide on hER␣ and SNURF activation of pERE 3 . ZR-75 cells were transfected with 1 g of pERE 3 , 0.25 g of CMV␤-gal, 3 ng of hER␣ alone or in combination with 10 ng of SNURF, and different amounts of NR-box peptide expression plasmids. Cells were treated with Me 2 SO or 10 nM E2, harvested, and assayed for luciferase activity as described under "Materials and Methods." B, effect of GRIP1 NR-box peptide on HE19 and SNURF activation of pERE 3 . ZR-75 cells were transfected with 1 g of pERE 3 , 0.25 g of pCMV␤-gal, 20 ng of HE19 alone or in combination with 25 ng of SNURF, and increasing amounts of pM-GRIP1-NR-box as indicated. Cells were treated with either 10 nM E2 or Me 2 SO, harvested, and assayed for luciferase activity as described under "Materials and Methods." Results presented in panels A and B are expressed as the means Ϯ S.E. for three replicate experiments, and significantly (p Ͻ 0.05) decreased activity induced by the NR-box peptide is indicated by an asterisk. F, SNURF.
FIG. 4. Multiple regions on SNURF are required for coactivation of pERE 3 in ZR-75 cells.
A, coactivation of ER␣ by wild-type and mutant SNURF constructs. ZR-75 cells were transfected with 1 g of pERE 3 , 0.25 g of pCMV␤-gal, and 15 ng of either wt, deletion, or mutant SNURF constructs treated with 10 nM E2 or Me 2 SO, and luciferase activity was determined as described under "Materials and Methods." The SNURF point mutants are starred (CS1 SNURF: C136S, C139S; CS2 SNURF: C177S, C180S; CS3 SNURF: C136S, C139S, C177S, C180S). Results are expressed as the means Ϯ S.E. for three replicate experiments, and significant (p Ͻ 0.05) coactivation by SNURF is indicated by an asterisk. Immunoblot analysis of wild-type and selected SNURF variants indicated that comparable levels of protein were expressed (data not shown). B, interaction of various SNURF constructs with ER␣ in a mammalian two-hybrid assay. ZR-75 cells were transfected with 1 g of 5ϫGAL-luciferase reporter gene, 0.25 g of pCMV␤-gal, 500 ng of pM-ER␣, and 250 ng of either empty pVP-16, pVP-SNURF, or the various pVP-16-SNURF deletions or point mutations as indicated, and luciferase activity was determined as described under "Materials and SNURF Interactions with Other Coactivators-Coactivation of ER␣ by SNURF is ligand-dependent, requires repositioning of helix 12, and is lost in ER␣ constructs containing D538N, E542Q, and D545N mutations. Our results suggest that AF2-interacting proteins enhance recruitment of SNURF, and therefore, functional interactions of SNURF with prototypical SRCs, DRIP 205, and p300 were investigated. The results showed that although SNURF and SRCs alone coactivated ER␣-dependent transactivation in ZR-75 cells transfected with pERE 3 , combinations of SNURF plus various amounts of SRC-1 gave responses that were less than additive and not significantly higher than observed for SNURF alone (Fig. 6A) . Similar results were obtained using various amounts of SRC-2, SRC-3, DRIP 205, or p300, suggesting that these prototypical coactivators are not involved in SNURF-mediated coactivation on an ERE.
Previous studies report that SNURF interacts with TBP in vitro (54) , and TBP also interacts with ER␣ and potentiates AF2-dependent transactivation of an ERE promoter (81) . Therefore, we investigated cooperative coactivation of ER␣ by SNURF/TBP (Fig. 6B) . The results show that transfection of TBP or SNURF alone coactivated ER␣-dependent transactivation and cotransfection with TBP (10 -100 ng), plus SNURF (10 ng) expression plasmids gave greater than additive responses. Moreover, coactivation of ER␣ by TBP alone or SNURF plus TBP was decreased by cotransfection with the NR-box peptide (Fig. 6C) , as observed for coactivation of ER␣ by SNURF alone (Fig. 3A) . TBP binds the C-terminal RING domain of SNURF (54) , and cotransfection of TBP and CS2-SNURF (RING domain mutant) did not cooperatively enhance ER␣-mediated transactivation (Fig. 6D) . TBP did not cooperatively coactivate ER␣ in cells transfected with ⌬1-20 SNURF (interacts with ER␣ but not DNA) or ⌬31-65 SNURF (interacts with DNA but not ER␣), suggesting that cooperative coactivation of ER␣ by TBP/SNURF is dependent on domains of SNURF that bind TBP, ER␣, and DNA. DISCUSSION Halachmi et al. (82) first reported ligand-dependent interactions of p160 and p140 coactivators with the AF2 region of ER␣, and subsequent studies have identified an increasing number of coactivator/cointegrator proteins that enhance transactivation of one or more NRs. Studies showing that SRC-1, CBP/ p300, and p300/CBP-associated factor not only enhance NR action but also exhibit histone acetyltransferase activity and are consistent with a model for some coactivators where catalysis of histone acetylation facilitates access of transcription factor complexes to NR-responsive elements. However, ongoing studies show that other NR coactivator proteins exhibit multiple activities, and these include TRIP/SUG1, a component of the PA700 proteosome complex (83) ity group proteins (87); Zac1, a zinc finger transcription factor (88); p68, an RNA helicase (89); CARM1, an arginine methyltransferase (90); TIF1, a protein kinase (83); caveolins, proteins that interact with signaling molecules (91); and SRA, a steroid receptor RNA activator (92) . These results suggest that NR coactivation may involve more than one class of coactivators, and the potential complexities associated with multiple pathways are consistent with the subtle ligand-, tissue-and genespecific action of NRs.
The AR zinc finger region has been used in two-hybrid assays to identify a series of AR coactivators that include protein inhibitor of STAT (PIAS) proteins (93, 94) and SNURF, a novel RING finger protein. SNURF interacts with the zinc finger region of AR, ER, and PR and in coactivation studies with the AR in COS-1 and CV-1 cells. SNURF enhanced both basal and AR-dependent promoter activity, and similar results were observed using an assay system for PR-mediated transactivation (54, 55) . Using deletion and point mutants of SNURF, it is clear that there are major differences in SNURF coactivation of AR and ER␣. AR interacts with an extensive N-terminal region of SNURF (amino acids 1-121) (54, 55) , whereas in a mammalian two-hybrid assay, only deletions of amino acids 31-65 and mutations of both zinc fingers in the C-terminal RING domain resulted in loss of SNURF-ER␣ interactions in ZR-75 cells (Fig.  4B) . In contrast, coactivation of ER␣ by SNURF required almost an intact protein since ⌬66 -98SNURF was the only deletion/mutant construct of SNURF that was active. These results suggest that SNURF coactivation of ER␣ requires not only direct SNURF-ER␣ binding but also other domains of SNURF that do not bind ER␣ but may be important for recruiting other nuclear factors. Wild-type SNURF had minimal effects on basal reporter gene activity of an ERE in ZR-75 cells, whereas SNURF caused a 4-and Ͼ10-fold enhancement of E2-induced activity in cells transfected with ER␣ and HE19, respectively ( Figs. 1 and 2) . Differences in the magnitude of enhancement of ER␣ and HE19 by SNURF may be due to an inhibitory effect associated with the AF1 domain of ER␣ even though SNURF does not directly interact with AF1 in mammalian two-hybrid assays (Fig. 4D) . In contrast, AR-dependent transcription of an androgen response element/glucocorticoid FIG. 6 . Cooperative coactivation of ER␣ by SNURF and TBP. A, SRC-1 plus SNURF interactions. ZR-75 cells were transfected with 1 g of pERE 3 , 0.25 g of ␤-gal, 3 ng of hER␣ expression plasmid, 10 ng of SNURF, and different amounts of SRC-1 expression plasmid. After treatment with Me 2 SO or E2, luciferase activity (Norm. Luc. Activity) was determined as described under "Materials and Methods." B, TBP plus SNURF interactions. ZR-75 cells were transfected with 1 g of pERE 3 , 0.25 g of ␤-gal, 3 ng of hER␣ expression plasmid, and different amounts of SNURF and/or TBP expression plasmid. After treatment with E2 or Me 2 SO, luciferase activity was determined as described under "Materials and Methods." C, NR-box inhibition. Cells were treated as described in A using variable amounts of SNURF and/or TBP and NR-box peptide expression plasmid. D, cooperative interactions of TBP with wild-type and variant (var.) forms of SNURF. Cells were treated as described in A using 10 ng of TBP alone or in combination with 10 ng of wild-type or variant expression plasmids. Results are expressed as the means Ϯ S.E. for three replicate experiments, and significant (p Ͻ 0.05) coactivation (Fig. 6A) or inhibition with NR-box peptide (Fig. 6C) is indicated with an asterisk. In panels B and D, significant (p Ͻ 0.05) coactivation of ER␣ by wild-type or variant SNURF expression plasmids is indicated with an asterisk; significant cooperative interactions of TBP with wild-type or variant SNURF expression plasmids are indicated (a).
response element promoter was enhanced only with the RING finger mutant CS1-SNURF and not by wild-type SNURF (54) .
Results of binding and transactivation studies (Figs. 1-4 ) support a novel mechanism for SNURF-mediated coactivation of ER␣. We recently showed that the N-terminal region of SNURF (amino acids [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] is required for nonspecific DNA binding (95) , and deletion of this domain also resulted in loss of ER␣ coactivation (Fig. 4A) . The importance of the ⌬1-20 region for SNURF coactivation of ER␣ is not due to disruption of SNURF-ER␣ binding (Fig. 4B) , suggesting that SNURF interactions with DNA may be important for its coactivator activity. The chromatin immunoprecipitation assay results confirm that SNURF and ER␣ bind transfected ERE (Fig. 5A) , and the interaction of SNURF with this promoter in untreated (zero time) ZR-75 cells is consistent with our coactivation model in which SNURF is bound to the promoter before interaction with ER␣ (Fig. 7) . Studies on wild-type/mutant SNURF-ER␣ interactions show that SNURF mutants that do not interact with ER␣ are also inactive as coactivators (Fig. 4, A and B) ; however, several SNURF deletion mutants that interact with ER␣ do not exhibit coactivation activity, suggesting that interactions with ER␣ are not sufficient for coactivation.
Coactivation of ER␣ by SNURF is ligand-dependent and observed for E2 but not for the antiestrogen ICI 182,780 (Fig.  4C) ; moreover, SNURF enhanced ER␣-mediated transactivation in cells transfected with ER␣ or HE19 (Figs. 1A and 2A) but not in cells transfected with mutant ER␣ and HE19 expression plasmids containing D538N, E542Q, and D545N point mutations in helix 12 of AF2 (Fig. 2, B and C) . The LXXLL or NR-box motifs in SRCs and some other coactivators interact with the AF2-helix 12 region of ER␣, and the inhibitory effects of the GRIP1-NR-box polypeptide on SNURF coactivation of ER␣ (Fig. 3) further confirms the importance of helix 12 in this process and parallels the inhibitory effects of NR-box polypeptides on SRC coactivation (80) . These results suggest that the model for SNURF coactivation of ER␣ also requires ligand-dependent repositioning of helix 12 and recruitment of other AF2-interacting coactivators/nuclear factors that cooperatively act with SNURF (Fig. 7) .
Cooperative or synergistic coactivator-NR interactions involving two or more coactivators were previously reported (85, 96 -99) . Coactivator-associated arginine methyltransferase (CARM1) and a related methyltransferase enhanced ER␣ action only in the presence of GRIP1 (96, 97) ; CBP/p300 further increased coactivation in CV-1 cells, and this was dependent on binding of both CBP/p300 and CARM1 to two different domains on GRIP1. Another study showed that ligand-dependent coactivation of ER␣ by SRC-1 and CBP in SW-13 carcinoma cells required the coactivator BRIG1, a human homolog of yeast SWI/SNF-2 family of nuclear ATPases (85) . Two recent reports on enhanced NR coactivation by SRC-1 exhibit some similarities with our studies on SNURF-ER␣ interactions. Oct-1 interacts with the AR and enhances recruitment of SRC-1 and androgen response element-dependent promoter activity in COS-7 cells (98) . However, these interactions are promoterspecific and require both AR and Oct-1 DNA binding sites. their enhancement by other nuclear factors suggests that SNURF coactivation of ER␣ may also involve cooperative interactions with SRCs. Cooperative interactions of SNURF with several AF2-interacting proteins including SRC-1, SRC-2 (GRIP1), SRC3 (A1B1), DRIP205, and p300 were investigated in ZR-75 cells transfected with pERE 3 . These interactions were minimal or less than additive (data not shown), indicating that recruitment of these coactivators is not involved in cooperative enhancement of ER␣-mediated transactivation by SNURF.
Sadovsky et al. (81) extensively investigated enhanced transcriptional activation of ER␣ by TBP using several E2-responsive promoters. TBP binds to AF1 and AF2 of ER␣ and in transactivation studies; TBP enhanced ligand-independent constitutive AF1 activity. In contrast, TBP strongly coactivated ligand-dependent ER␣-and HE19-mediated transactivation, and these interactions were not observed using mouse ER containing mutations that blocked AF2 function (81) . Our results with SNURF coactivation of ER␣ are similar to those previously reported for TBP (81) , and because SNURF also binds TBP (54), we further investigated potential interactions of SNURF/TBP on ER␣ activation of an ERE promoter in ZR-75 cells.
Cotransfection of SNURF and TBP cooperatively enhanced ER␣-mediated transactivation, and this interaction was dependent on SNURF domains required for interactions with TBP, ER␣, and DNA (Fig. 6) . The inhibitory effects of the NR-box peptide also confirmed the importance of the AF2 region of ER␣ and helix 12, which is required for SNURF-dependent cooperative coactivation of ER␣ and interactions of TBP with ER␣ (81) . The model for SNURF/TBP-dependent coactivation (Fig. 7) involves protein-protein and protein-DNA interactions and a specific sequence of steps that includes ligand binding, repositioning of helix 12, and recruitment of TBP and then SNURF to form the transcriptionally active complex in which all three proteins can physically interact (54, 55, 81) . These results describe a novel coactivation mechanism in which SNURF selectively interacts with TBP but not other AF2-interacting proteins to enhance ER␣-mediated transactivation. The pathway outlined in Fig. 7 does not exclude a role for other nuclear factors, and currently, we are investigating the mechanisms of SNURF coactivation of ER␣ and ER␣/Sp1 and the participation of additional nuclear coregulatory proteins.
